SARS-CoV-2 originated in animals and is now easily transmitted between people. Sporadic detection of natural cases in animals alongside successful experimental infections of pets, such as cats, ferrets and dogs, raises questions about the susceptibility of animals under natural conditions of pet ownership. Here we report a large-scale study to assess SARS-CoV-2 infection in 817 companion animals living in northern Italy, sampled at a time of frequent human infection. No animals tested PCR positive. However, 3.4% of dogs and 3.9% of cats had measurable SARS-CoV-2 neutralizing antibody titers, with dogs from COVID-19 positive households being significantly more likely to test positive than those from COVID-19 negative households. Understanding risk factors associated with this and their potential to infect other species requires urgent investigation.

One Sentence Summary SARS-CoV-2 antibodies in pets from Italy.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late December 2019 in Wuhan, Hubei province, China , possibly as a spillover from bats to humans , and rapidly spread worldwide becoming a pandemic. Although the virus is believed to spread almost exclusively by human-to-human transmission, there are concerns that some animal species may contribute to the ongoing SARS-CoV-2 pandemic epidemiology. To date, sporadic cases of SARS-CoV-2 infection have been reported in dogs and cats. These include detection of SARS-CoV-2 RNA in respiratory and/or fecal specimens of dogs and cats with or without clinical signs (5−7), as well as of specific antibodies in sera from pets from coronavirus disease 2019 (COVID-19) affected areas (7,8).

I posted about this a while back, as a treatment. I’m glad people are catching up.

Some doctors are now trying to deliver 100% oxygen to COVID patients in decompression chambers long used to treat divers with the bends.

---

As a New York University medical researcher who works once a week in an emergency room, Dr. David Lee had the luxury of time to think like a scientist while also treating coronavirus patients whose lungs kept giving out. In every case, he saw the same thing: Their blood was starved of oxygen.

One day an idea hit him: Could hyperbaric oxygen therapy, best known for treating divers with the bends, help stave off the need for ventilators and perhaps reduce deaths?

Physiologically it made sense to him, but he soon learned it was also complicated. The therapy, which involves delivering 100% oxygen straight to patients inside a pressurized chamber, is often met with skepticism by the wider medical community because fringe supporters have long touted it as a virtual cure-all without scientific evidence.

The first-of-its-kind, randomized, placebo-controlled, phase 1/2a trial will assess patients hospitalized at Florida and South Dakota institutions.

Researchers announce the first patient has been dosed in a trial testing remestemcel-L, a stem cell therapy, in severe COVID-19 patients on ventilators.

Testing of an experimental COVID-19 stem cell therapy has begun in the US. The therapy has been developed to treat hospitalised COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) who are on ventilators. A total of 300 are expected to be recruited into the randomised, placebo-controlled trial.